Targeted therapy is becoming increasingly important and has improved the overall survival for patients with NSCLC. BRAF V600E mutations (Val600Glu) are observed in 1-2% of lung cancer and play a major role in targeted therapy by providing an opportunity for affected patients as possible allocable target. In Austria an effective therapy is available with Dabrafenib and Trametinib. The aim of this retrospective analysis was to support ongoing research on the frequency of this promising genetic alteration by determining the prevalence of BRAF V600E mutations among Austrian NSCLC patients. We also examined clinical characteristics of these patients.